Gsk (GLAXF) EBT Margin Growth (1y) (2010 - 2026)
Gsk (GLAXF) EBT Margin Growth (1y) (2010 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
EBT Margin Growth (1y) (Qtr) |
| 1 |
Gsk |
93,699,046.73 Bn |
93,699,041.77 Bn |
7.76 Bn |
6.00 |
| 2 |
Eli Lilly |
1,012.06 Bn |
1,006.77 Bn |
16.22 Bn |
1,755.00 |
| 3 |
Johnson & Johnson |
560.67 Bn |
538.62 Bn |
15.96 Bn |
-3,737.00 |
| 4 |
AbbVie |
402.20 Bn |
392.85 Bn |
10.78 Bn |
-552.00 |
| 5 |
Merck |
298.59 Bn |
292.94 Bn |
12.09 Bn |
-5,950.00 |
| 6 |
Amgen |
188.77 Bn |
176.74 Bn |
5.87 Bn |
-3.00 |
| 7 |
Gilead Sciences |
160.22 Bn |
152.49 Bn |
5.52 Bn |
1,234.00 |
| 8 |
Pfizer |
148.19 Bn |
135.42 Bn |
-1.21 Bn |
372.00 |
| 9 |
Bristol Myers Squibb |
116.72 Bn |
106.26 Bn |
8.07 Bn |
168.00 |
| 10 |
Gsk |
- |
- |
7.76 Bn |
6.00 |
| Date | Value |
|---|
| Mar 31, 2026 |
6.00 |
| Dec 31, 2025 |
-767.00 |
| Sep 30, 2025 |
2,794.00 |
| Jun 30, 2025 |
467.00 |
| Mar 31, 2025 |
964.00 |
| Dec 31, 2024 |
-887.00 |
| Sep 30, 2024 |
-2,118.00 |
| Jun 30, 2024 |
-872.00 |
| Mar 31, 2024 |
-903.00 |
| Dec 31, 2023 |
638.00 |
| Sep 30, 2023 |
906.00 |
| Jun 30, 2023 |
1,475.00 |
| Mar 31, 2023 |
-169.00 |
| Dec 31, 2022 |
-2,968.00 |
| Sep 30, 2022 |
-506.00 |
| Jun 30, 2022 |
-540.00 |
| Mar 31, 2022 |
907.00 |
| Dec 31, 2021 |
4,845.00 |
| Jun 30, 2021 |
-1,631.00 |
| Mar 31, 2021 |
-13.00 |
